Login / Signup

Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019.

Sean Wei Xiang OngWilnard Yeong Tze TanYi-Hao ChanSiew-Wai FongShanshan W HowlandLisa F P NgYee Sin LeoDavid Chien Boon LyeBarnaby Edward Young
Published in: Clinical & translational immunology (2020)
Treatment with COX-2 inhibitors was not associated with an increase in adverse outcomes. Its potential for therapeutic use as an immune modulator warrants further evaluation in a large randomised controlled trial.
Keyphrases
  • coronavirus disease
  • randomized controlled trial
  • risk assessment
  • combination therapy
  • human health
  • nitric oxide
  • nitric oxide synthase
  • replacement therapy